COLO B Coloplast A/S Class B

Coloplast A/S - Announcement no. 08/2021 - Sustainability Report 2020/21

Coloplast A/S - Announcement no. 08/2021 - Sustainability Report 2020/21

The purpose of Coloplast inherently supports social development in society. By making life easier for people with intimate healthcare needs, we enable people to be active and take part in society. It is our priority to make sustainability easier for our users without compromising product safety and clinical performance. Our users do not choose their conditions and they should never be concerned about using Coloplast products in any way. Respect and responsibility are core values at Coloplast and Coloplast works continuously to improve and ensure responsible operations. Coloplast therefore has a solid foundation to build on.

As part of our corporate strategy, Strive25, we made a commitment to run our company in a more sustainable way. We are focused on improving our products and packaging, reducing emissions and have an on-going commitment to responsible operations. To deliver on our 2025 ambitions, we will invest up to DKK 250 million over the next five years.

During FY 2020/21, Coloplast made key achievements on production waste recycling, which increased to 58% from 41% in 2019/20, we made a 10% reduction on scope 3 emissions pre product, compared to base year 2018/19, and finally, we reduced the number of injuries in the work place.

Please find our Sustainability Report 2020/21 in below link.



 

For further information, please contact

  

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Ellen Bjurgert

Vice President, Investor Relations

Tel. /

Email:

Aleksandra Dimovska

Sr. Manager, Investor Relations

Tel. /

Email:                                                                        

Press and the media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website

 

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-11.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment



EN
01/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 2,150 shares at 463.200DKK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

 PRESS RELEASE

Coloplast udnævner Gavin Wood som ny CEO

Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...

 PRESS RELEASE

Coloplast appoints Gavin Wood as new CEO

Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-do...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch